CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced the appointments of K. Reed Clark, Ph.D. to the newly created position of vice president, manufacturing and Terrence R. Flotte, M.D., Celia and Isaac Haidak Professor in Medical Education, dean of the School of Medicine and provost and executive deputy chancellor of the University of Massachusetts Medical School (UMMS) to the company’s scientific advisory board.
“Reed brings extensive translational experience in AAV gene therapy delivery techniques and manufacturing to the Dimension technical leadership team, which will be invaluable as we advance our lead program in hemophilia B toward the clinic,” said Sam Wadsworth, Ph.D., chief scientific officer, Dimension Therapeutics. “Terry is a luminary in the gene therapy field and his scientific guidance and expertise will be critical as we work to develop safe and effective treatments for rare diseases. I am pleased to welcome Reed and Terry to the Dimension team.”
K. Reed Clark, Ph.D.
Dr. Clark is a veteran molecular virologist and gene therapist with extensive experience in preclinical and translational adeno-associated virus (AAV) gene therapy studies. Prior to joining Dimension, Dr. Clark served as director of the cGMP Clinical Manufacturing Facility and Preclinical Vector Core, and associate center director at the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. Dr. Clark also served on the faculty of the Ohio State University as a professor in the Department of Pediatrics, College of Medicine. His laboratory has made seminal discoveries in scalable AAV engineered mammalian cell lines, FPLC purification of AAV vectors and improved AAV titration approaches using qPCR and wt-AAV free reporter cell lines. He has authored more than 50 peer-reviewed publications with a focus on utilizing AAV biologics for genetic vaccination and neuromuscular indications from pre-clinical proof of concept through early phase clinical trials. Through participation in multiple translational AAV programs, Dr. Clark has garnered extensive experience with multiple AAV based biologics that have progressed to early phase clinical testing. He has served as a member on the both the AAV2 and AAV8 reference standard committees, chair of the institutional IBC and multiple NIH and private peer review study sections. Dr. Clark received his B.S. in genetics and Ph.D. in molecular genetics from the Ohio State University and was a post-doctoral fellow in gene therapy at Nationwide Children’s Hospital.
Terrence R. Flotte, M.D.
Dr. Flotte is an internationally recognized pioneer in gene therapy. In addition to his roles at UMMS, Dr. Flotte serves on the Liaison Committee on Medical Education and the ASGCT Advisory Council, setting policy and goals for promoting gene therapy research through public education, scientific meetings and scientific committees. Prior to UMMS, Dr. Flotte served on the faculty of the University of Florida, most recently as chair of the Department of Pediatrics. Earlier, Dr. Flotte served on the faculty of Johns Hopkins University where he and his colleagues became the first to use AAV as gene therapy delivery technique in adults with cystic fibrosis. He is the author of more than 260 peer-reviewed papers and has received numerous honors and awards, including the Society for Pediatric Research E. Mead Johnson Award for Outstanding Scientific Contributions and the University of Florida Faculty Research Prize in Clinical Science. Dr. Flotte received his undergraduate degree in biological sciences from the University of New Orleans and his M.D. from the Louisiana State University School of Medicine.
About Dimension Therapeutics
Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Launched by Fidelity Biosciences in 2013, the Dimension team comprises biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. The company is focused on building its adeno-associated virus (AAV) therapeutic discovery platform and advancing multiple gene therapy programs in rare diseases through partnerships with REGENX Biosciences and the University of Pennsylvania, which provide Dimension with exclusive gene therapy intellectual property and preferred access to multiple best-in-class AAV vector systems. For more information, please visit www.dimensiontx.com.